Varicella zoster vaccines and their implications for development of HSV vaccines

Virology

Volumn 435, Issue 1, 2013, Pages 29-36

  Gershon, Anne A ^a  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

Herpes simplex virus; Vaccination; Vaccine efficacy; Vaccine safety; Varicella zoster virus

Indexed keywords

HERPES SIMPLEX VACCINE; LIVE VACCINE; VARICELLA ZOSTER VACCINE;

CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; DRUG SAFETY; HERPES ZOSTER; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPROMISED PATIENT; IMMUNOGENICITY; INCUBATION TIME; NATURAL KILLER CELL; NONHUMAN; OPEN READING FRAME; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEROCONVERSION; SEROTYPE; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN DISEASE; UNSPECIFIED SIDE EFFECT; VARICELLA ZOSTER VIRUS; VIRUS LATENCY; VIRUS REACTIVATION; VIRUS STRAIN;

CHICKENPOX; CHILD; CHILD, PRESCHOOL; HERPES SIMPLEX; HERPES SIMPLEX VIRUS VACCINES; HERPES ZOSTER; HERPES ZOSTER VACCINE; HERPESVIRUS 3, HUMAN; HUMANS; IMMUNITY, CELLULAR; MIDDLE AGED; SIMPLEXVIRUS; SURVIVAL RATE; VACCINATION; VACCINES, ATTENUATED;

HUMAN HERPESVIRUS 3; SIMPLEXVIRUS;

EID: 84870653762     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2012.10.006     Document Type: Review

References (117)

1. Abendroth A., Arvin A. Immune evasion mechanisms of varicella-zoster virus. Arch. Virol. Suppl. 2001, 17:99-107.
2. Arvin A.M., Pollard R.B., Rasmussen L., Merigan T. Selective impairment in lymphocyte reactivity to varicella-zoster antigen among untreated lymphoma patients. J. Infect. Dis. 1978, 137:531-540.
3. Arvin A.M., Moffat J.F., Sommer M., Oliver S., Che X., Vleck S., Zerboni L., Ku C.C. Varicella-zoster virus T cell tropism and the pathogenesis of skin infection. Curr. Top. Microbio. Immunol. 2010, 342:189-209.
4. Asano Y., Albrecht P., Vujcic L.K., Quinnan G.V., Kawakami K., Takahashi M. Five-year follow-up study of recipients of live varicella vaccine using enhanced neutralization and fluorescent antibody membrane antigen assays. Pediatrics 1983, 72:291-294.
5. Asano Y., Suga S., Yoshikawa T., Kobayashi H., Yazaki T., Shibata M., Tsuzuki K., Ito S. Experience and reason: twenty year follow up of protective immunity of the Oka live varicella vaccine. Pediatrics 1994, 94:524-526.
6. Berger T.M., Caduff J.H., Gebbers J.-O. Fatal varicella-zoster virus antigen-positive giant cell arteritis of the central nervous system. Ped. Infect. Dis. J. 2000, 19:653-656.
7. Birlea M., Arendt G., Orhan E., Schmid D.S., Bellini W.J., Schmidt C., Gilden D., Cohrs R.J. Subclinical reactivation of varicella zoster virus in all stages of HIV infection. J. Neurol. Sci. 2011, 304(1-2):22-24.
8. Blumenthal D.T., Shacham-Shmueli E., Bokstein F., Schmid D.S., Cohrs R.J., Nagel M.A., Mahalingam R., Gilden D. Zoster sine herpete: virologic verification by detection of anti-VZV IgG antibody in CSF. Neurology 2011, 76(5):484-485.
9. Bochud P.Y., Magaret A.S., Koelle D.M., Aderem A., Wald A. Polymorphisms in TLR2 are associated with increased viral shedding and lesional rate in patients with genital herpes simplex virus Type 2 infection. J. Infect. Dis. 2007, 196(4):505-509.
10. Breuer, J., Grose, C., Norberg, P., Tipples, G., Schmid, D.S., 2010. A proposal for a common nomenclature for viral clades that form the species varicella-zoster virus: summary of VZV Nomenclature Meeting 2008, Barts and the London School of Medicine and Dentistry, 24-25 July 2008. J. Gen. Virol., vol. 91(Pt 4), pp. 821-828.
11. Brisson M., Gay N., do W.J., Andrews N.J. Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox. Vaccine 2002, 20:2500-2507.
12. Brunell P.A. Transmission of chickenpox in a school setting prior to the observed exanthem. Am. J. Dis. Child. 1989, 143:1451-1452.
13. Burke B.L., Steele R.W., Beard O.W., Wood J.S., Cain T.D., Marmer D.J. Immune responses to varicella-zoster in the aged. Arch. Intern. Med. 1982, 142:291-293.
14. Casanova J.L., Abel L., Quintana-Murci L. Human TLRs and IL-1Rs in host defense: natural insights from evolutionary, epidemiological, and clinical genetics. Annu. Rev. Immunol. 2011, 29:447-491.
15. Casrouge A., Zhang S.Y., Eidenschenk C., Jouanguy E., Puel A., Yang K., Alcais A., Picard C., Mahfoufi N., Nicolas N., Lorenzo L., Plancoulaine S., Senechal B., Geissmann F., Tabeta K., Hoebe K., Du X., Miller R.L., Heron B., Mignot C., de Villemeur T.B., Lebon P., Dulac O., Rozenberg F., Beutler B., Tardieu M., Abel L., Casanova J.L. Herpes simplex virus encephalitis in human UNC-93B deficiency. Science 2006, 314(5797):308-312.
16. Castex F., Guillemot F., Talbodec N., Colombel J.F., Paris J.C., Cortot A. Association of an attack of varicella and an achalasia. Am. J. Gastroenterol. 1995, 90(7):1188-1189.
17. Centers-for-Disease-Control Prevention of varicella: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb. Mort. Wkly. Rep. 1996, 45:1-36. July 12, 1996.
18. Centers-for-Disease-Control Prevention of Varicella. Morb. Mort. Wkly. Rep 2007, 56:1-55.
19. Centers-for-Disease-Control Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2007, 56:1-40.
20. Chaves S.S., Gargiullo P., Zhang J.X., Civen R., Guris D., Mascola L., Seward J.F. Loss of vaccine-induced immunity to varicella over time. N. Engl. J. Med. 2007, 356(11):1121-1129.
21. Chaves S.S., Haber P., Walton K., Wise R.P., Izurieta H.S., Schmid D.S., Seward J.F. Safety of varicella vaccine after licensure in the United States: experience from reports to the vaccine adverse event reporting system, 1995-2005. J. Infect. Dis. 2008, 197(Suppl 2):S170-S177.
22. Chen J., Gershon A.A., Li Z., Cowles R.A., M.D.G. Varicella zoster virus (VZV) infects and establishes latency in enteric neurons. J. Neurovirol. 2011, 17:578-589.
23. Chen J.J., Zhu Z., Gershon A.A., Gershon M.D. Mannose 6-phosphate receptor dependence of varicella zoster virus infection in vitro and in the epidermis during varicella and zoster. Cell 2004, 119(7):915-926.
24. Cinque P., Bossolasco S., Vago L., Fornara C., Lipari S., Racca S., Lazzarin A., Linde A. Varicella-zoster virus (VZV) DNA in cerebrospinal fluid of patients infected with human immunodeficiency virus: VZV disease of the central nervous system or subclinical reactivation of VZV infection?. Clin. Infect. Dis. 1997, 25(3):634-639.
25. Cohen J.I., Straus S.E., Arvin A. Varicella-Zoster Virus: Replication, Pathogenesis, and Management. Fields Virology 2007, Lippincott Williams and Wilkins, Philadelphia, pp. 2773-2818. Fifth ed. D.M. Knipe, P.M. Howley (Eds.).
26. Cohrs, R.J., Gilden, D., 2012. Colorado Alphaherpesvirus Latency Symposium #2. J. Neurovirol.
27. Cohrs R.J., Mehta S.K., Schmid D.S., Gilden D.H., Pierson D.L. Asymptomatic reactivation and shed of infectious varicella zoster virus in astronauts. J. Med. Virol. 2008, 80(6):1116-1122.
28. Corey L., Wald A. Maternal and neonatal herpes simplex virus infections. N. Engl. J. Med. 2009, 361(14):1376-1385.
29. Crumpacker C. Absence of exposure to varicella does not increase the risk of zoster. Clin. Infect. Dis. 2011, 53:412-413.
30. De La Blanchardiere A., Rozenberg F., Caumes E., Picard O., Lionnet F., Livartowski J., Coste J., Sicard D., Lebon P., Salmon-Ceron D. Neurological complications of varicella-zoster virus infection in adults with human immunodeficiency virus infection. Scand. J. Infect. Dis. 2000, 32(3):263-269.
31. Donahue J.G., Choo P.W., Manson J.E., Platt R. The incidence of herpes zoster. Arch. Intern. Med. 1995, 155(15):1605-1609.
32. Dueland A.N., Devlin M., Martin J.R., Mahalingam R., Cohrs R., Manz H., Trombley I., Gilden D. Fatal varicella-zoster virus meningoradiculitis without skin involvement. Ann. Neurol. 1991, 29(5):569-572.
33. Edelman D.A., Antaki F., Basson M.D., Salwen W.A., Gruber S.A., Losanoff J.E. Ogilvie syndrome and herpes zoster: case report and review of the literature. J. Emerg. Med. 2009, 39(5):696-700.
34. Freeman E.E., Weiss H.A., Glynn J.R., Cross P.L., Whitworth J.A., Hayes R.J. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 2006, 20(1):73-83.
35. Gabel C., Dubey L., Steinberg S., Gershon M., Gershon.A. Varicella-zoster virus glycoproteins are phosphorylated during posttranslational maturation. J. Virol. 1989, 63:4264-4276.
36. Gaillat J., et al. Does monastic life predispose to the risk of Saint Anthony's fire (herpes zoster)?. Clin. Infect. Dis. 2011, 53:405.
37. Galea, S., Sweet, A., Gershon, A., LaRussa, P., Steinberg, S., Music, S., Sharrar, R., 2002. Fifth Annual Conference on Vaccine Research. Baltimore, M.D.
38. Galea S.A., Sweet A., Beninger P., Steinberg S.P., Larussa P.S., Gershon A.A., Sharrar R.G. The safety profile of varicella vaccine: a 10-year review. J. Infect. Dis. 2008, 197(Suppl. 2):S165-S169.
39. Garnett G.P., Dubin G., Slaoui M., Darcis T. The potential epidemiological impact of a genital herpes vaccine for women. Sex Transm. Infect. 2004, 80(1):24-29.
40. Gershon A., Chen J., LaRussa P., Steinberg S. Varicella-zoster virus. Manual of Clinical Microbiology 2007, 1537-1548. ASM Press, Washington, D.C. 9th ed. P.R. Murray, E. Baron, J. Jorgensen, M. Landry, M. Pfaller (Eds.).
41. Gershon A., Steinberg S., Brunell P.A. Zoster immune globulin: a further assessment. N. Engl. J. Med. 1974, 290:243-245.
42. Gershon, A., Takahashi, M., Seward, J.F., 2012. Live attenuated varicella vaccine. In: Vaccines. Plotkin S., Orenstein W., Offit P., (Eds.), 6th edition, wb Saunders, Philadelphia, Chapter 37.
43. Gershon A.A. Varicella vaccine: rare serious problems-but the benefits still outweigh the risks. J. Infect. Dis. 2003, 188(7):945-947.
44. Gershon A.A., Chen J., Davis L., Krinsky C., Cowles R., Reichard R., Gershon M. Latency of VZV in dorsal root, cranial nerve, and enteric ganglia in vaccinated children. Trans. Amer. Clin. Climatol. Assoc. 2012, 123:17-35.
45. Gershon A.A., Gershon M.D. Perspectives on vaccines against varicella-zoster virus infections. Curr. Top. Microbiol. Immunol. 2010, 342:359-372.
46. Gershon A.A., LaRussa P., Steinberg S. Live attenuated varicella vaccine: current status and future uses. Semin. Ped. Infect. Dis. 1991, 2:171-177.
47. Gershon A.A., Steinberg S., Gelb L. Clinical reinfection with varicella-zoster virus. J. Infect. Dis. 1984, 149:137-142. NIAID-Collaborative-Varicella-Vaccine-Study-Group.
48. Gershon A.A., Steinberg S., Gelb L. Live attenuated varicella vaccine: efficacy for children with leukemia in remission. J.A.M.A 1984, 252:355-362. NIAID-Collaborative-Varicella-Vaccine-Study-Group.
49. Gershon A.A., Steinberg S., LaRussa P., Hammerschlag M., Ferrara A. Immunization of healthy adults with live attenuated varicella vaccine. J. Infect. Dis. 1988, 158:132-137. NIAID-Collaborative-Varicella-Vaccine-Study-Group.
50. Gilden D., Cohrs R.J., Mahalingam R., Nagel M.A. Neurological disease produced by varicella zoster virus reactivation without rash. Curr. Top. Microbiol. Immunol. 2010, 342:243-253.
51. Gilden D.H., Wright R., Schneck S., Gwaltney J.M., Mahalingam R. Zoster sine herpete, a clinical variant. Ann. Neurol. 1994, 35:530-533.
52. Gold E. Serologic and virus-isolation studies of patients with varicella or herpes zoster infection. N. Engl. J. Med. 1966, 274:181-185.
53. Goldman G.S., King P.G. Review of the United States universal varicella vaccination program: Herpes zoster incidence rates, cost-effectiveness, and vaccine efficacy based primarily on the Antelope Valley Varicella Active Surveillance Project data. Vaccine 2012.
54. Gustafson T.L., Lavely G.B., Brauner E.R., Hutcheson R.H., Wright P., Schaffner W. An outbreak of airbirne nosocomial varicella. Pediatrics 1982, 70:550-556.
55. Hambleton S., Steinberg S.P., Larussa P.S., Shapiro E.D., Gershon A.A. Risk of herpes zoster in adults immunized with varicella vaccine. J. Infect. Dis. 2008, 197(Suppl 2):S196-S199.
56. Hardy I., Gershon A.A., Steinberg S.P., LaRussa P., et al. The incidence of zoster after immunization with live attenuated varicella vaccine. A study in children with leukemia. Varicella Vaccine Collaborative Study Group. N. Engl. J. Med. 1991, 325(22):1545-1550.
57. Hata A., Asanuma H., Rinki M., Sharp M., Wong R.M., Blume K., Arvin A.M. Use of an inactivated varicella vaccine in recipients of hematopoietic- cell transplants. N. Engl. J. Med. 2002, 347(1):26-34.
58. Jean-Philippe P., Freedman A., Chang M.W., Steinberg S.P., Gershon A.A., LaRussa P.S., Borkowsky W. Severe varicella caused by varicella-vaccine strain in a child with significant T-cell dysfunction. Pediatrics 2007, 120(5):e1345-e1349.
59. Johnston C., Koelle D.M., Wald A. HSV-2: in pursuit of a vaccine. J. Clin. Invest. 2011, 121(12):4600-4609.
60. Junker A.K., Angus E., Thomas E. Recurrent varicella-zoster virus infections in apparently immunocompetent children. Ped. Infect. Dis. J 1991, 10:569-575.
61. Kennedy P.G., Cohrs R.J. Varicella-zoster virus human ganglionic latency: a current summary. J. Neurovirol. 2011, 16(6):411-418.
62. Kimberlin D.W., Whitley R.J. Neonatal herpes: what have we learned. Semin. Pediatr. Infect. Dis. 2005, 16(1):7-16.
63. Kramer J.M., LaRussa P., Tsai W.C., Carney P., Leber S.M., Gahagan S., Steinberg S., Blackwood R.A. Disseminated vaccine strain varicella as the acquired immunodeficiency syndrome-defining illness in a previously undiagnosed child. Pediatrics 2001, 108(2):E39.
64. Ku C.C., Besser J., Abendroth A., Grose C., Arvin A.M. Varicella-zoster virus pathogenesis and immunobiology: new concepts emerging from investigations with the SCIDhu mouse model. J. Virol. 2005, 79(5):2651-2658.
65. Ku C.C., Zerboni L., Ito H., Graham B.S., Wallace M., Arvin A.M. Varicella-zoster virus transfer to skin by t cells and modulation of viral replication by epidermal cell interferon-{alpha}. J. Exp. Med. 2004, 200(7):917-925.
66. Laing K.J., Dong L., Sidney J., Sette A., Koelle D.M. Immunology in the Clinic Review Series; focus on host responses T cell responses to herpes simplex viruses. Clin. Exp. Immunol. 2011, 167(1):47-58.
67. Leclair J.M., Zaia J., Levin M.J., Congdon R.G., Goldmann D. Airborne transmission of chickenpox in a hospital. N. Engl. J. Med. 1980, 302:450-453.
68. LaRussa P., Lungu O., Hardy I., Gershon A., Steinberg S., Silverstein S. Restriction fragment length polymorphism of polymerase chain reaction products from vaccine and wild-type varicella-zoster virus isolates. J. Virol. 1992, 66:1016-1020.
69. Leroux-Roels I., Leroux-Roels G., Clement F., Vandepapeliere P., Vassilev V., Ledent E., Heineman T.C. A Phase 1/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein E subunit vaccine candidate in young and older adults. J. Infect. Dis 2012.
70. Levin M.J., DeBiasi R.L., Bostik V., Schmid D.S. Herpes zoster with skin lesions and meningitis caused by 2 different genotypes of the Oka varicella-zoster virus vaccine. J. Infect. Dis. 2008, 198(10):1444-1447.
71. Levy O., Orange J.S., Hibberd P., Steinberg S., LaRussa P., Weinberg A., Wilson S.B., Shaulov A., Fleisher G., Geha R.S., Bonilla F.A., Exley M. Disseminated varicella infection due to vaccine (Oka) strain varicella-zoster virus in a patient with a novel deficiency in natural killer cells. J. Infect. Dis. 2003, 188:948-953.
72. Ljungman P., Lonnqvist B., Gahrton G., Ringden O., Sundqvist V.-A., Wahren B. Clinical and subclinical reactivations of varicella-zoster virus in immunocompromised patients. J. Infect. Dis. 1986, 153:840-847.
73. Luby J., Ramirez-Ronda C., Rinner S., Hull A., Vergne-Marini P. A longitudinal study of varicella zoster virus infections in renal transplant recipients. J. Infect. Dis. 1977, 135:659-663.
74. Mahamud A., Marin M., Nickell S., Shoemaker T., Zhang J., Bialek S. Herpes zoster-related deaths in the united states: validity of death certificates and mortality rates. Clin. Infect. Dis. 2012, 1979-2007:54.
75. Marin M., Meissner H.C., Seward J.F. Varicella prevention in the United States: a review of successes and challenges. Pediatrics 2008, 122(3):e744-e751.
76. Marin M., Zhang J.X., Seward J.F. Near elimination of varicella deaths in the US after implementation of the vaccination program. Pediatrics 2011, 128(2):214-220.
77. Mehta S.K., Cohrs R.J., Forghani B., Zerbe G., Gilden D.H., Pierson D.L. Stress-induced subclinical reactivation of varicella zoster virus in astronauts. J. Med. Virol. 2004, 72(1):174-179.
78. Michalik D.E., Steinberg S.P., LaRussa P.S., Edwards K.M., Wright P.F., Arvin A.M., Gans H.A., Gershon A.A. Primary vaccine failure after 1 dose of varicella vaccine in healthy children. J. Infect. Dis. 2008, 197(7):944-949.
79. Mitka M. FDA approves shingles vaccine: herpes zoster vaccine targets older adults. JAMA 2006, 296(2):157-158.
80. Moffat J.F., Stein M.D., Kaneshima H., Arvin A.M. Tropism of varicella-zoster virus for human CD4+ and CD8+ T lymphocytes and epidermal cells in SCID-hu mice. J. Virol. 1995, 69:5236-5242.
81. Ouwendijk W.J., Choe A., Nagel M.A., Gilden D., Osterhaus A.D., Cohrs R.J., Verjans G.M. Restricted VZV transcription in human trigeminal ganglia obtained early after death. J. Virol 2012.
82. Ouwendijk W.J., Mahalingam R., Traina-Dorge V., van Amerongen G., Wellish M., Osterhaus A.D., Gilden D., Verjans G.M. Simian varicella virus infection of Chinese rhesus macaques produces ganglionic infection in the absence of rash. J. Neurovirol. 2012, 18(2):91-99.
83. Oxman M.N., Levin M.J., Johnson G.R., Schmader K.E., Straus S.E., Gelb L.D., Arbeit R.D., Simberkoff M.S., Gershon A.A., Davis L.E., Weinberg A., Boardman K.D., Williams H.M., Zhang J.H., Peduzzi P.N., Beisel C.E., Morrison V.A., Guatelli J.C., Brooks P.A., Kauffman C.A., Pachucki C.T., Neuzil K.M., Betts R.F., Wright P.F., Griffin M.R., Brunell P., Soto N.E., Marques A.R., Keay S.K., Goodman R.P., Cotton D.J., Gnann J.W., Loutit J., Holodniy M., Keitel W.A., Crawford G.E., Yeh S.S., Lobo Z., Toney J.F., Greenberg R.N., Keller P.M., Harbecke R., Hayward A.R., Irwin M.R., Kyriakides T.C., Chan C.Y., Chan I.S., Wang W.W., Annunziato P.W., Silber J.L. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N. Engl. J. Med. 2005, 352(22):2271-2284.
84. Pahud B.A., Glaser C.A., Dekker C.L., Arvin A.M., Schmid D.S. Varicella zoster disease of the central nervous system: epidemiological, clinical, and laboratory features 10 years after the introduction of the varicella vaccine. J. Infect. Dis. 2011, 203(3):316-323.
85. Peng T., Zhu J., Klock A., Phasouk K., Huang M.L., Koelle D.M., Wald A., Corey L. Evasion of the mucosal innate immune system by herpes simplex virus type 2. J. Virol. 2009, 83(23):12559-12568.
86. Posavad C.M., Remington M., Mueller D.E., Zhao L., Magaret A.S., Wald A., Corey L. Detailed characterization of T cell responses to herpes simplex virus-2 in immune seronegative persons. J. Immunol. 2010, 184(6):3250-3259.
87. Preblud S., Arbeter A., Proctor E., Starr S., Plotkin S. Susceptibility of vaccine strains of varicella-zoster virus to antiviral compounds. Antimicrob. Agn. Chemo. 1984, 25:417-421.
88. Pui J.C., Furth E.E., Minda J., Montone K.T. Demonstration of varicella-zoster virus infection in the muscularis propria and myenteric plexi of the colon in an HIV-positive patient with herpes zoster and small bowel pseudo-obstruction (Ogilvie's syndrome). Am. J. Gastroenterol. 2001, 96(5):1627-1630.
89. Quinlivan M.L., Jensen N.J., Radford K.W., Schmid D.S. Novel genetic variation identified at fixed loci in ORF62 of the Oka varicella vaccine and in a case of vaccine-associated herpes zoster. J. Clin. Microbiol. 2012.
90. Ragozzino M.E., Melton L.F., Kurland L., Chu C.P., Perry H.O. Population-based study of herpes zoster and its sequelae. Medicine 1982, 61:310-316.
91. Robertson C.S., Martin B.A., Atkinson M. Varicella-zoster virus DNA in the oesophageal myenteric plexus in achalasia. Gut 1993, 34(3):299-302.
92. Schmader K., Oxman M., Levin M., Johnson G., Zhang J., Betts R., Morrison V., Gelb L., Guatelli J., Harbecke R., Pachucki C., Keay S., Menzies B., Griffin M., Kauffman C., Marques A., Toney J., Keller P., Li X., Chan I., Annunziato P. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clin. Infect. Dis 2012.
93. Schmader K., Studenski S., MacMillan J., Grufferman S., Cohen S.J. Are stressful life events risk factors for herpes zoster?. J. Am. Geriart. Soc. 1990, 38:1188-1194.
94. Schmader K.E., Levin M.J., Gnann J.W., McNeil S.A., Vesikari T., Betts R.F., Keay S., Stek J.E., Bundick N.D., Su S.C., Zhao Y., Li X., Chan I.S., Annunziato P.W., Parrino J. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin. Infect. Dis. 2012, 54(7):922-928.
95. Shah S.S., Wood S.M., Luan X., Ratner A.J. Decline in varicella-related ambulatory visits and hospitalizations in the United States since routine immunization against varicella. Pediatr. Infect. Dis. J. 2011, 29(3):199-204.
96. Shapiro E.D., Vazquez M., Esposito D., Holabird N., Steinberg S.P., Dziura J., Larussa P.S., Gershon A.A. Effectiveness of 2 doses of varicella vaccine in children. J. Infect. Dis. 2011, 203(3):312-315.
97. Sharrar R.G., LaRussa P., Galea S., Steinberg S., Sweet A., Keatley M., Wells M., Stephenson W., Gershon A. The postmarketing safety profile of varicella vaccine. Vaccine 2000, 19:916-923.
98. Son, M., Shapiro, E., LaRussa, P., Neu, N., Michalik, D., Meglin, M., Bitar, W., Jurgrau, A., Flynn, P., Gershon, A., 2008. Vaccination of Children with Perinatal HIV Infection Protects against Varicella and Zoster. In: Pediatric Acdemic Societies Annual Meeting. Honolulu, HI.
99. Son M., Shapiro E.D., LaRussa P., Neu N., Michalik D.E., Meglin M., Jurgrau A., Bitar W., Vasquez M., Flynn P., Gershon A.A. Effectiveness of varicella vaccine in children infected with HIV. J. Infect. Dis. 2010, 201(12):1806-1810.
100. Spiegel R., Miron D., Lumelsky D., Horovitz Y. Severe meningoencephalitis due to late reactivation of Varicella-Zoster virus in an immunocompetent child. J. Child Neurol. 2010, 25(1):87-90.
101. Stratman E. Visceral zoster as the presenting feature of disseminated herpes zoster. J. Am. Acad. Dermatol. 2002, 46(5):771-774. pe=abs&id=a119091&target=.
102. Straus S. Clinical and biological differences between recurrent herpes simplex virus and varicella-zoster virus infections. JAM 1989, 262:3455-3458.
103. Takahashi M., Otsuka T., Okuno Y., Asano Y., Yazaki T., Isomura S. Live vaccine used to prevent the spread of varicella in children in hospital. Lancet 1974, 2:1288-1290.
104. Thomas S., Wheeler J., Hall A.J. Contacts with varicella or with children and protection against herpes zoster in adults: a case-control study. Lancet 2002, 360(Aug 31):678-682.
105. Tseng H.F., Smith N., Marcy S.M., Sy L.S., Jacobsen S.J. Incidence of herpes zoster among children vaccinated with varicella vaccine in a prepaid health care plan in the United States, 2002-2008. Pediatr. Infect. Dis. J. 2009, 28(12):1069-1072.
106. Tsolia M., Gershon A., Steinberg S., Gelb L. Live attenuated varicella vaccine: evidence that the virus is attenuated and the importance of skin lesions in transmission of varicella-zoster virus. J. Pediatr. 1990, 116:184-189.
107. Ulloa-Gutierrez R. Varicella vaccine and fatal outcome in leukaemia. Lancet 2007, 369(9576):1860.
108. Ussery X.T., Annunziato P., Gershon A., Reid B., Lungu O., Langston C., Silverstein S., Lee K., Baker C.J. Congenital varicella-zoster infection and Barrett's esophagus. J. Infect. Dis. 1998, 178:539-543.
109. Vazquez, M., 2012. Pediatric Academic Specialties. Boston, MA.
110. Vazquez M., LaRussa P., Gershon A., Steinberg S., Freudigman K., Shapiro E. The effectiveness of the varicella vaccine in clinical practice. N. Engl. J. Med. 2001, 344:955-960.
111. Vazquez M., LaRussa P.S., Gershon A.A., Niccolai L.M., Muehlenbein C.E., Steinberg S.P., Shapiro E.D. Effectiveness over time of varicella vaccine. JAM 2004, 291(7):851-855.
112. Verjans G.M., Hintzen R.Q., van Dun J.M., Poot A., Milikan J.C., Laman J.D., Langerak A.W., Kinchington P.R., Osterhaus A.D. Selective retention of herpes simplex virus-specific T cells in latently infected human trigeminal ganglia. Proc. Natl. Acad. Sci., USA 2007, 104(9):3496-3501.
113. Williams V., Gershon A., Brunell P. Serologic response to varicella-zoster membrane antigens measured by indirect immunofluorescence. J. Infect. Dis. 1974, 130:669-672.
114. Wilson A., Sharp M., Koropchak C.M., Ting S.F., Arvin A.M. Subclinical varicella-zoster virus viremia, herpes zoster, and T lymphocyte immunity to varicella-zoster viral antigens after bone marrow transplantation. J. Infect. Dis. 1992, 165(1):119-126.
115. Weller T.H. Varicella and herpes zoster: changing concepts of the natural history, control, and importance of a not-so-benign virus. N. Engl. J. Med. 1983, 309:1362-1368. , 1434-1440.
116. Zhang S.Y., Jouanguy E., Ugolini S., Smahi A., Elain G., Romero P., Segal D., Sancho-Shimizu V., Lorenzo L., Puel A., Picard C., Chapgier A., Plancoulaine S., Titeux M., Cognet C., von Bernuth H., Ku C.L., Casrouge A., Zhang X.X., Barreiro L., Leonard J., Hamilton C., Lebon P., Heron B., Vallee L., Quintana-Murci L., Hovnanian A., Rozenberg F., Vivier E., Geissmann F., Tardieu M., Abel L., Casanova J.L. TLR3 deficiency in patients with herpes simplex encephalitis. Science 2007, 317(5844):1522-1527.
117. Zhu J., Koelle D.M., Cao J., Vazquez J., Huang M.L., Hladik F., Wald A., Corey L. Virus-specific CD8+ T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation. J. Exp. Med. 2007, 204(3):595-603.